| Autor: |
Firoz WA; UC Davis Comprehensive Cancer Center, Sacramento, CA., Sen F; Department of Radiology, University of California, Davis, Sacramento, CA., Kiuru M; Department of Dermatology, University of California, Davis, Sacramento, CA; Department of Pathology and Laboratory Medicine, University of California, Davis, Sacramento, CA., Huang V; Department of Dermatology, University of California, Davis, Sacramento, CA., Riess JW; UC Davis Comprehensive Cancer Center, Sacramento, CA; Division of Hematology/Oncology, Department of Internal Medicine, University of California, Davis, Sacramento, CA. Electronic address: jwriess@ucdavis.edu. |
| Jazyk: |
angličtina |
| Zdroj: |
Clinical lung cancer [Clin Lung Cancer] 2024 Jun; Vol. 25 (4), pp. 380-383. Date of Electronic Publication: 2024 Jan 30. |
| DOI: |
10.1016/j.cllc.2024.01.008 |
| Abstrakt: |
Competing Interests: Disclosure This case report did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. WAF, FS, VH, and MK have no conflicts of interest to report. MK receives funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, under award number K23AR074530. JWR has consulting or advisory roles with Blueprint, Beigene, Daiichi Sankyo, EMD Serano, Janssen, Regeneron, Sanofi, Biodesix, Bayer, Turning Point, Bristol Myers Squibb, Jazz Pharmaceuticals, Novartis, Roche/Genentech, Boehringer Ingelheim, Merck, and SeaGen. JWR also receives research funding to institution from Merck, Novartis, AstraZeneca, Spectrum, Revolution Medicines, Arrivent, IO Biotech, and Vitrac. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect